Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Type 2 inflammation in asthma and other airway diseases

Jorge Maspero, Yochai Adir, Mona Al-Ahmad, Carlos A. Celis-Preciado, Federico D. Colodenco, Pedro Giavina-Bianchi, Hani Lababidi, Olivier Ledanois, Bassam Mahoub, Diahn-Warng Perng, Juan C. Vazquez, Arzu Yorgancioglu
ERJ Open Research 2022 8: 00576-2021; DOI: 10.1183/23120541.00576-2021
Jorge Maspero
1Fundacion CIDEA (Centro de Investigacion de Enfermedades Alergicas y Respiratorias), University of Buenos Aires, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jorge.maspero@fundacioncidea.org.ar
Yochai Adir
2Pulmonary Division, Lady Davis Carmel Medical Center, Faculty of Medicine, The Technion, Institute of Technology, Haifa, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mona Al-Ahmad
3Microbiology Dept, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos A. Celis-Preciado
4Pulmonary Unit, Internal Medicine Department, Hospital Universitario San Ignacio, Bogota, Colombia
5Faculty of Medicine, Pontificia Universidad Javeriana, Bogota, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Federico D. Colodenco
6Pulmonology, Hospital De Rehabilitación Respiratoria María Ferrer, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pedro Giavina-Bianchi
7Clinical Immunology and Allergy Division, University of Sao Paulo, Sao Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hani Lababidi
8King Fahad Medical City, Riyadh, Saudi Arabia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Ledanois
9Sanofi Genzyme, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bassam Mahoub
10Dept of Pulmonary Medicine and Allergy and Sleep Medicine, Rashid Hospital, Dubai, United Arab Emirates
11Dept of Medicine and Chest Disease, University of Sharjah, Sharjah, United Arab Emirates
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diahn-Warng Perng
12Taipei Veterans General Hospital, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan C. Vazquez
13Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Juan C. Vazquez
Arzu Yorgancioglu
14Dept of Chest Diseases, Faculty of Medicine, Manisa Celal Bayar University, Manisa, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Chronic inflammatory airway diseases, including asthma, chronic rhinosinusitis, eosinophilic COPD and allergic rhinitis are a global health concern. Despite the coexistence of these diseases and their common pathophysiology, they are often managed independently, resulting in poor asthma control, continued symptoms and poor quality of life. Understanding disease pathophysiology is important for best treatment practice, reduced disease burden and improved patient outcomes.

The pathophysiology of type 2 inflammation is driven by both the innate immune system triggered by pollutants, viral or fungal infections involving type 2 innate lymphoid cells (ILC2) and the adaptive immune system, triggered by contact with an allergen involving type 2 T-helper (Th2) cells. Both ILC2 and Th2 cells produce the type-2 cytokines (interleukin (IL)-4, IL-5 and IL-13), each with several roles in the inflammation cascade. IL-4 and IL-13 cause B-cell class switching and IgE production, release of pro-inflammatory mediators, barrier disruption and tissue remodelling. In addition, IL-13 causes goblet-cell hyperplasia and mucus production. All three interleukins are involved in trafficking eosinophils to tissues, producing clinical symptoms characteristic of chronic inflammatory airway diseases.

Asthma is a heterogenous disease; therefore, identification of biomarkers and early targeted treatment is critical for patients inadequately managed by inhaled corticosteroids and long-acting β-agonists alone. The Global Initiative for Asthma guidelines recommend add-on biological (anti IgE, IL-5/5R, IL-4R) treatments for those not responding to standard of care. Targeted therapies, including omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab and tezepelumab, were developed on current understanding of the pathophysiology of type 2 inflammation. These therapies offer hope for improved management of type 2 inflammatory airway diseases.

Abstract

Asthma is a heterogenous disease. Targeted therapies have been developed based on the pathophysiology of type 2 inflammation. These therapies offer hope for improved management of type 2 inflammatory airway diseases. https://bit.ly/3HCkrvQ

Introduction

Asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) are mainly type 2 inflammatory diseases which, when left uncontrolled, are characterised by debilitating symptoms, including shortness of breath, airway obstruction (asthma) or nasal obstruction, loss of smell, and nasal discharge (CRSwNP) [1, 2]. Persistent type 2 inflammation continuously damages the epithelium, creating a vicious cycle whereby the inflammatory response escalates, exacerbating the already debilitating clinical symptoms [3]. These conditions are often managed as single entities, yet their coexistence is common and linked with a shared pathological mechanism. People with allergic asthma can commonly present with allergic rhinitis, and patients with rhinosinusitis with nasal polyps often have comorbid asthma [4]. These comorbidities are associated with overtreatment of asthma with high-dose inhaled corticosteroids (ICS) and poor asthma control, with up to 10% of patients experiencing severe exacerbations, impairment of lung function and quality of life (QoL), and associated healthcare costs [5–7], despite receiving high doses of oral corticosteroids (OCS) [8, 9].

Comprising four component characteristics, including bronchoconstriction, airway inflammation, airway hyperresponsiveness and chronic remodelling of airways, our understanding of the inflammatory mechanisms and immune cell interplay on these components is essential for the development of future treatments for type 2 asthma and comorbidities. Given their frequency, this article focuses on the burden, underlying pathophysiology and management of type 2 inflammation associated with upper and lower airway diseases.

Epidemiology

Asthma is a complex disease caused by both environmental and genetic factors, and is characterised by chronic wheezing and airflow obstruction, which occurs because of inflammation in the airways of the lungs [10]. Triggered by contact with an allergen, atopic asthma is the most common form of asthma, affecting 70–90% of children and ∼50% of adult patients with asthma [11]. The prevalence of atopic diseases is increasing, with allergic asthma, along with atopic dermatitis and allergic rhinitis being described as the milestones of an “atopic march” [12]. Chronic inflammatory airway diseases such as asthma, CRSwNP, COPD with type 2 inflammation, and allergic rhinitis, are prevalent and represent a serious global health concern, creating a substantial clinical and economic burden [13].

Asthma affects 339 million people worldwide [14] and, in 2016, resulted in ∼420 000 deaths [15]. The prevalence of CRSwNP, measured using a patient questionnaire, is estimated at ∼1.1–4.3%, and increases with age [16]. Approximately 15–37% of patients with COPD have persistent blood eosinophils >2%, which may indicate presence of type 2 inflammation [17, 18]. The prevalence of allergic rhinitis varies widely, from 1.6% to 54% across the world [19]. These patients often have evidence of type 2 inflammation, affecting up to 51% of patients with uncontrolled asthma, 55–70% of patients with severe asthma [20–22], 80% of patients with CRSwNP [23, 24], 49% of patients with CRSsNP [25], 15–37% of patients with COPD [17] and 100% of patients with allergic rhinitis (table 1) [19]. Accordingly, type 2 inflammation is responsible of a number of airway diseases that often coexist together.

View this table:
  • View inline
  • View popup
TABLE 1

Airway diseases driven by type 2 inflammation [17–24, 26–41]

Type 2 inflammatory airway diseases are common and represent a substantial clinical burden, with debilitating symptoms, reduced QoL and work productivity [44–47]. The frequent systemic corticosteroid use can lead to increased risk of related adverse effects [26, 48, 49], as well as the substantial burden of comorbid type 2 inflammatory diseases [47, 50–53].

Burden of disease

Asthma

Despite access to ICS and long-acting β-agonist (LABA) combination therapy, patients with uncontrolled asthma frequently suffer from poorly controlled comorbidities as well. These patients have impaired lung function, associated with higher risk of asthma exacerbations, further worsening of their type 2 comorbidities. Asthma and severe CRSwNP are frequently associated with other coexisting type 2 inflammatory diseases such as nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (NSAID-ERD), aspirin-exacerbated respiratory disease (AERD), allergic rhinitis, eosinophilic oesophagitis, atopic dermatitis and type 2 eosinophilic COPD [26–29].

Poorly controlled asthma symptoms in patients treated with prescription medicines are common, and affect between 40% and 54% of adults with asthma in the United States [5, 54]. Patients with poorly controlled asthma have significantly reduced health-related QoL, greater overall work impairment and higher healthcare resource utilisation than those with well-controlled asthma [5, 54, 55]. Moreover, patients with very poorly controlled asthma have been shown to incur more than twice the indirect costs and one and a half times the direct healthcare costs compared with those incurred for well-controlled patients [5]. Patients with well-controlled asthma have been reported to have better physical and mental health; fewer emergency room visits, hospitalisation days and medical provider visits; and lower levels of overall work productivity loss and activity impairment [55]. Although the cost of treating asthma is significant, with an estimated USD 18 billion being spent in the United States alone, about half of patients with asthma continue to be poorly controlled with ICS and LABA treatments [5]. Asthma exacerbations are associated with significant morbidity and account for a substantial proportion of asthma-related costs. Therefore, effective management of asthma and related comorbidities, prevention of subsequent asthma exacerbations and reduction of asthma severity are important to ensure reduction of healthcare costs as well as improvement in the QoL of patients with asthma [56, 57].

Extrapulmonary comorbidities contribute substantially to poor asthma control and a heightened disease burden. Guidelines state that patients with poorly controlled asthma should have a diagnosis confirmed, together with addressing comorbidities before phenotyping the pattern of inflammation [58]. Frequent asthma exacerbations are significantly associated with severe nasal sinusitis, chronic rhinosinusitis, psychological dysfunction, bronchiectasis, gastro-oesophageal reflux, obstructive sleep apnoea, vocal cord dysfunction, obesity, dysfunctional breathing and anxiety/depression [57, 59–65].

Allergic rhinitis and chronic rhinosinusitis/CRSwNP

Allergic rhinitis and chronic rhinosinusitis are characterised by inflammation and irritation in the nasal cavities following allergen exposure and are common in patients with asthma, affecting 55–60% and 22–45% of patients, respectively [30, 59, 63, 66, 67]. Indeed, computed tomography has shown that sinusitis may be present in 84% of patients with asthma [68]. Likewise, the increased prevalence of nasal polyps has been associated with asthma severity [69].

Chronic rhinosinusitis is a substantially heterogeneous disease, with patients commonly divided into two subgroups, those with nasal polyps (CRSwNP) and those without nasal polyps (CRSsNP). Although both forms of disease are driven by different inflammatory mechanisms [70, 71], many CRSsNPs can be eosinophilic or have high type 2 inflammation [16]. Patients with CRSwNP are particularly prone to developing asthma, with incidence up to 70%, depending on the degree of type 2 inflammation [72]. Patients with chronic rhinosinusitis have inflammation of the sinonasal mucosa, which results in nasal obstruction, facial pressure or pain, loss of smell and poor drainage lasting for >12 weeks. The surgical and medical management of chronic rhinosinusitis represents a large cost burden, and nasal polyp growth is present in 1–4% of the population of the United States [2, 70]. Notably, patients with CRSwNP may suffer from this condition for decades [72, 73]. In Europe and the United States, the majority of patients with CRSwNP have significant eosinophilic infiltration and elevated levels of IgE in their nasal polyp tissue [2]. Likewise, higher levels of eosinophils in the serum and sputum in these conditions suggest a close relationship between asthma and chronic rhinosinusitis [68].

Asthma and associated type 2 inflammatory airway diseases

Type 2 inflammatory airway diseases, such as asthma, CRSwNP, NSAID-ERD/AERD, eosinophilic COPD and allergic rhinitis often coexist in the same patient, and are driven by a similar underlying type 2 pathophysiology [31]. The risk of asthma symptoms increases with increasing presence of CRSwNP [74] along with the increased likelihood of poor asthma control [75, 76]. Likewise, the presence of a comorbid type 2 inflammatory disease increases the severity and clinical burden of CRSwNP, with disease severity being significantly greater in patients with CRSwNP and asthma versus those with CRSwNP alone [53]. The presence of a comorbid type 2 inflammatory disease has also been associated with an increased risk of recurrence of nasal polyps post-surgery in patients with CRSwNP [77].

The coexistence of type 2 inflammatory diseases is associated with greater decline in lung function and clinical outcomes in patients with asthma. A 5-year study of patients with recently diagnosed adult-onset asthma showed that the presence of comorbid nasal polyps was significantly associated with a greater decline in post-bronchodilator forced expiratory volume in 1 s (FEV1) per year [78]. Moreover, comorbid disease has been shown to increase disease burden in patients whose asthma is driven by type 2 inflammation, with the presence of rhinitis, nasal polyps or atopic dermatitis as independent predictors for future asthma exacerbations [79].

Both persistent uncontrolled asthma and CRSwNP contribute to the burden of disease and are common causes of sleep disturbance and fatigue. These conditions have been shown to lead to decreased daytime functioning and reduced QoL [45, 80], as well as having negative impacts on both physical and mental health [47, 81–83]. The impact of these diseases on work productivity and absenteeism has also been shown to result in substantial indirect costs. Almost half of CRSwNP patients awaiting surgery experiencing reduced productivity and a 40–60% overall work impairment in asthma patients despite receiving LABA or ICS treatment. Similarly, a study of >8000 asthma patients with comorbid COPD showed a significantly increased likelihood of severe exacerbations of asthma and COPD, versus healthy nonsmoker controls, with greater annual decline in FEV1 versus asthma or COPD alone [84].

Severe uncontrolled asthma or acute episodes of CRSwNP are frequently treated with OCS. However, this can contribute to the short- and long-term burden of disease. Short-term effects include mood and sleep disturbances, while long-term consequences include osteoporosis, gastrointestinal bleeds, type 2 diabetes, obesity, cataracts and glaucoma [1, 85]. All these conditions have been shown to contribute significantly to patients’ health concerns [86]. Moreover, the healthcare cost of OCS-related side-effects is substantial. Asthma patients with comorbid disease while on OCS generate twice as much healthcare cost compared with nonasthmatic patients [87]. Similarly, patients with CRSwNP taking OCS have higher total healthcare costs compared with those not taking OCS [88]. A systematic literature review over three decades of research has also shown a higher clinical and economic burden in patients with allergic rhinitis and asthma results, with a 1.2- to 2.1-fold increase in annual costs for these patients [89]. Similar results from a United States-based study showed substantially greater healthcare utilisation among patients with both asthma and COPD versus those with asthma or COPD alone, with medical service costs being five times greater in this group than in patients with asthma alone [89].

Type 2 inflammation: pathophysiology

Type 2 inflammation is driven by both the adaptive and innate arms of the immune system and underpins the pathophysiology of several chronic upper and lower airway diseases, including asthma, COPD, CRSwNP and allergic rhinitis [90–92]. Type 2 inflammation is driven by Th2 cells and group 2 innate lymphoid cells (ILC2), which produce the type 2 cytokines, including interleukin (IL)-4, IL-5 and IL-13, as well as other inflammatory mediators (tables 2 and 3) [31, 100–102]. Type 2 cytokines have a range of roles in the pathophysiology of type 2 inflammatory airway diseases. IL-5 plays a pivotal role in the differentiation and maturation of IL-5Rα+ eosinophil progenitors in the bone marrow, as well as their mobilisation and survival. In addition, IL-5 supports the development of other type 2 cells, including mast cells and basophils [103]. IL-4 and IL-13 both play a role in B-cell class switching and IgE production, leading to the degranulation of basophils and mast cells and subsequent release of pro-inflammatory mediators as well as barrier disruption and tissue remodelling [31, 91]. IL-13 is involved in goblet-cell hyperplasia and mucus production [31, 91], as well as smooth muscle contractility and hyperplasia [104]. Moreover, IL-13-mediated damage to the epithelial barriers is also associated with the development of mucus plugs as a consequence of mucus production [104].

View this table:
  • View inline
  • View popup
TABLE 2

Central drivers of type 2 inflammation interleukin (IL)-4 and IL-13 have unique and overlapping functions, contributing the pathophysiology of asthma, chronic rhinosinusitis with nasal polyps and allergic rhinitis [3, 31, 92, 93, 93–99]

View this table:
  • View inline
  • View popup
TABLE 3

Pathophysiological features of type 2 inflammatory airway diseases [3, 31, 92–99]

IL-4, IL-13 and IL-5 are all involved in trafficking of eosinophils to tissues (figure 1) [3, 31, 105–107]. These common pathophysiological effects, driven by type 2 inflammation, manifest as clinical symptoms, including nasal polyps, loss of smell, and nasal obstruction in CRSwNP [3], and impaired lung function, wheezing, shortness of breath, chest tightness and coughing in asthma [1]. The key and central cytokines for type 2 airway diseases include IL-4 and IL-13. IL-4 upregulates differentiation of naïve Th0 cells into Th2 cells, which produce IL-4, IL-13 and IL-5, thus creating a cyclical effect [31]. IL-4, IL-5 and IL-13 also induce chemokines (i.e. eotaxin-3, thymus- and activation-regulated chemokine) and vascular cell adhesion molecule 1, which promote migration and trafficking of inflammatory cells, including eosinophils, to the site of inflammation [3, 31]. Eosinophils are activated by IL-5 and are recruited to the airway directly or indirectly by IL-4, IL-13 and IL-5 [31].

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Key cytokines driving type 2 inflammatory airway diseases [3, 31, 104–106]. S. aureus: Staphylococcus aureus; TSLP: thymic stromal lymphopoietin; IL: interleukin; ILC2: type 2 innate lymphoid cells; Th: T-helper; TARC: thymus and activation-regulated chemokine; CRSwNP: chronic rhinosinusitis with nasal polyps; PGD2: prostaglandin D2.

Type 2 inflammation in asthma

More specific to asthma, IL-13 has effects on goblet and airway smooth muscle cells, which impact mucus secretion, smooth muscle contractility and basement membrane thickening [31]. Moreover, in asthma, along with the production of mucus, IL-13 facilitates airway obstruction by tethering to mucus-producing cells in the epithelium and impairing mucociliary transport, identified by the expression of the mucin 5AC (MUC5AC) protein, which is considered to be a marker of airway goblet cells and mucus hypersecretion [108], leading to the development of mucosal plugs. Nitric oxide production is also upregulated by IL-13 in asthma [109].

Type 2 inflammation in nasal polyposis

In patients with CRSwNP, an increased inflammatory response results from an innate immune function, causing defects in the nasal epithelial barrier, with subsequent reduced secretion of innate host defence molecules, loss of the epithelial barrier and impaired mucus clearance. The result is colonisation by bacteria and fungi and loss of barrier function and accumulation of antigens/allergens in the sinonasal cavity, which can access mucosal tissue and activate eosinophils, mast cells and other immune effector cells, as well as T- and B-cell recruitment [70]. Therefore, this defective barrier plays an important role in the initiation and maintenance of chronic rhinosinusitis and is a common feature across type 2 inflammatory diseases. Studies of epithelial barrier dysfunction in upper and lower airways have shown key pathophysiological roles of IL-4 and IL-13, contributing to both bronchial (asthma) and sinonasal (CRSwNP) epithelial barrier dysfunction through disruption of epithelial junctions and thus increasing epithelial permeability [110].

Goblet-cell hyperplasia, excess mucus production and mucociliary dysfunction are also features of type 2 inflammatory remodelling in both asthma and CRSwNP [104, 111–113].

In CRSwNP, IL-4 and IL-13 induce activation of M2-type macrophages, which contribute to the pathogenesis of CRSwNP by inducing fibrin deposition, oedematous remodelling and polyp formation, while IL-13 has additional effects on goblet cells, mucus production and nasal epithelial cell mucociliary differentiation [3, 114]. Likewise, in patients with upper airway disease such as CRSwNP, IL-13 supports alterations in nasal epithelium, inducing MUC5AC, in turn impairing ciliary function [115].

As mentioned, IL-4 and IL-13 are key and central type 2 cytokines in type 2 inflammation and have an important role to play in driving airway and tissue remodelling in type 2 inflammatory diseases of the upper and lower airways [3, 31, 91, 116–118]. Airway wall thickening in both asthma and CRSwNP is driven by overexpression of both IL-4 and IL-13, inducing fibrosis through transforming growth factor-β [119]. Type 2 inflammation is also key to the remodelling processes involved in polyp formation, with IL-4 and IL-13 causing a decrease in tight junction proteins and activation of epithelial-to-mesenchymal transition induction [3] and membrane thickening. Additionally, IL-4 and IL-13 contribute to remodelling and nasal polyp formation in CRSwNP by inducing activation of macrophages to M2 macrophages and inhibiting fibrin degradation (IL-13) [3, 114].

Type 2 inflammation in allergic rhinitis

The pathophysiology of allergic rhinitis is similar to that of other upper inflammatory airway diseases, such as CRSwNP. Type 2 inflammatory cells and mediators, including Th2 cells and ILC2, drive the type 2 response cascade leading to the release of further response mediators, including the interleukins IL-4, IL-13 and IL-5, and eosinophils [31]. As with CRSwNP, these type 2 inflammatory drivers result in goblet-cell hyperplasia, mucus production and barrier dysfunction. The role of IgE in allergic rhinitis is very important: on allergen contact, cross-linking IgE bound to its receptor induces mast cells to release granules and subsequently chemical mediators, resulting in inflammation [120–122].

Other comorbidities

Type 2 inflammation underpins multiple other comorbid diseases including atopic dermatitis, allergic bronchopulmonary aspergillosis [123], AERD, ocular diseases, eosinophilic oesophagitis and other gastrointestinal disorders, and food allergies.

Elevated IgE levels are common in patients with atopic dermatitis who have history of allergic rhinitis and asthma [124] and up to one-third of children with atopic dermatitis develop asthma [125]. Moreover, both IL-4 and IL-13 play key roles in modulation of the epidermal barrier and development of atopic dermatitis, with many children having higher levels of serum IL-13 than healthy children [126].

Allergic bronchopulmonary aspergillosis, sometimes classified as a subtype of asthma, affects approximately 5 million patients with asthma, representing an 8.4% comorbidity [123]. It is an IgE-mediated disease, with increased IgE and IgG antibodies and peripheral blood eosinophilia [6], resulting in chronic mucus hypersecretion and accelerated loss of lung function [127]. As in AERD, both upper airway pathology and lower airway pathology in NSAID-ERD patients are characterised by chronic and extensive eosinophilic mucosal inflammation related to abnormalities of both cyclo-oxygenase- and lipoxygenase-derived arachidonic acid metabolism [128]. Food allergy (e.g. eggs) could also be associated with asthma, especially in early life [129]. The predisposition for asthma in patients with food allergies is clear and should not be ignored, with preventable interactions manifesting in the form of respiratory symptoms and bronchial hyperreactivity during food-induced anaphylaxis, and severe asthma resulting from the cross-reactivity between pollen and allergens from fruits and vegetables [130].

Biomarkers for type 2 inflammation

The heterogeneous nature of asthma and its comorbidities requires identification of biomarkers and timely introduction of early and effective personalised medicine for those not being adequately managed by ICS and LABA alone. Inflammatory cytokines (IL-4, IL-13 and IL-5) and their receptors, among others, are important targets for treating type 2 asthma, since they promote an increase in inflammation. Fractional exhaled nitric oxide (FeNO), thymus and activation-regulated chemokine (TARC), eotaxin, periostin, IgE and blood eosinophil counts have all emerged as predominant biomarkers for type 2 inflammatory airway diseases, providing opportunities for better disease targeting, improving patients’ health-related QoL, and reducing direct and indirect cost burdens associated with ineffective management of asthma in the long term. FeNO and blood eosinophil count are produced through the action of cytokine mediators [31, 100–102, 131–134]. Chemotactic biomarkers of type 2 inflammation include eotaxin-3 and TARC, which are chemoattractants stimulated by IL-4 and IL-13; however, no single biomarker pathway is solely responsible for type 2 inflammation in airway diseases.

Recent asthma guidelines recommend the use of type 2 biomarkers to establish the cause of asthma and determine the best course of treatment [1]. The Global Initiative for Asthma (GINA) [1] defines type 2 airway inflammation when the following criteria are met: blood eosinophils ≥150 cells·µL−1 and/or FeNO ≥20 ppb and/or sputum eosinophils ≥2% and/or asthma clinically allergen-driven and/or need for maintenance OCS (repeat blood eosinophils and FeNO up to three times, on lowest possible OCS dose) [1]. However, despite candidate biomarkers being identified, there are no recommendations as yet for testing in CRSwNP. Endotyping, phenotyping, treatment response and biomarkers are a rapidly evolving fields and further research is needed [2].

Management of severe asthma and other airway diseases with type 2 inflammation

Guidelines

The goals of asthma management include achieving control of symptoms and maintaining normal activity levels for physical and social development, while minimising the risk of disease exacerbation, impaired lung development, and side-effects associated with medications [1, 85, 86]. The GINA 2021 guidelines’ stepwise approach to the management of asthma (figure 2) [1] ranges from steps 1 and 2 with as-needed reliever medications (low-dose ICS-formoterol as a preferred option or a short-acting β-agonist as an alternative) and low-dose ICS as a controller, through steps 3 and 4 treatment with low- to medium-dose maintenance of ICS-formoterol or ICS/LABA, to step 5 with a high dose of dual controllers or the addition of a third controller with long-acting muscarinic antagonists and biological therapies. Low-dose OCS could be an alternative, but side-effects should be considered. Despite these comprehensive guidelines, the management of moderate and severe forms of atopic diseases such as asthma remain a challenge for physicians. It is apparent that comorbidities are important in the management of severe asthma, as they may contribute to poor disease control by both exacerbating and mimicking symptoms of asthma, resulting in overtreatment of asthma symptoms and increased costs. Given the heterogeneous pathobiology and multiple phenotypes of asthma and its associated comorbidities, there is a need for a personalised approach for the diagnosis and subsequent management of asthma. Type 2 inflammation underlies type 2 asthma and associated comorbidities, and there is a need to fully understand allergic, eosinophilic and combined phenotypes to ensure improvements in the management of this disease. Nevertheless, the key treatment objective for all patients with asthma includes full control of the disease with minimum side-effects.

FIGURE 2
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2

The Global Initiative for Asthma stepwise approach to control symptoms and minimise future asthma risk in adults and adolescents aged >12 years [1]. ICS: inhaled corticosteroid; SABA: short-acting β-agonist; LAMA: long-acting muscarinic antagonist; IL: interleukin; LABA: long-acting β-agonist; LTRA: leukotriene receptor antagonist; HDM: house dust mite; SLIT: sublingual allergen immunotherapy; OCS: oral corticosteroid; FeNO: exhaled nitric oxide fraction; s.c.: subcutaneous; i.v.: intravenous; CBC: complete blood count; CRP: C-reactive protein; HRCT: high-resolution computed tomography; DLCO: diffusing capacity of the lung for carbon monoxide; ANCA: antineutrophil cytoplasmic antibodies; CT: computed tomography; BNP: brain natriuretic peptide.

Current guidelines, including those from GINA (2021) [1], the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) (2020) [2] and the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) (2019) [16] recognise that side-effects associated with standard of care (i.e. standard care services) should be minimised, while acknowledging the major role of type 2 inflammation in asthma and CRSwNP, as well as other inflammatory airway diseases. The GINA guidelines [1] recommend considering add-on type-2-targeted biological treatments for patients with exacerbations or poor symptom control on high-dose ICS+LABA, and who have allergic or eosinophilic biomarkers, or need maintenance OCS. These guidelines include the use of either an anti-IL-4 receptor as add-on treatment, anti-IgE or anti-IL-5 in patients with severe asthma who do not adequately respond to the standard of care. Anti-IL-4Rα agents block the signalling of both IL-4 and IL-13 [135]. The EPOS guidelines [2] also highlight the role of type 2 inflammation in CRSwNP and the impact of comorbid diseases on CRSwNP, highlighting the need to take these diseases into consideration when treating CRSwNP. Likewise, the EUFOREA [16] guidelines recommend development of a multidisciplinary integrated care pathway in daily practice where all patients with chronic rhinosinusitis receive at least one systematic assessment for asthma and allergic rhinitis, ideally using a validated questionnaire along with systematic evaluation of their upper and lower airways at every clinical visit.

Standard of care and unmet needs

The majority of type 2 inflammatory airway diseases, such as asthma and CRSwNP, remain poorly controlled with the current standard of care [48, 136]. A substantial proportion (23–32%) of asthma patients treated with ICS and LABA have been shown not to achieve GINA-defined well-controlled asthma after 1 year of ICS±LABA use [137]. Similarly, although surgical removal of nasal polys is the standard of care in patients with severe CRSwNP, following oral or systemic corticosteroid treatment, 80% of these patients experience recurrence of polyps. The overuse of systemic corticosteroids is associated with adverse effects, including immunosuppression, weight gain, diabetes, osteoporosis, glaucoma, anxiety and depression and cardiovascular disease [138, 139].

Standard of care treatments have nonspecific anti-inflammatory effects on a range of cell types, often targeting symptoms, but do not specifically target cytokines (IL-4, IL-13 and IL-5) involved in inflammation, and can lead to serious treatment-related adverse effects and costs [1, 2, 140]. This unmet need has led to the development of cytokine-targeted therapies and the biological-focused management of type 2 inflammatory airway diseases. Although IL-13 can be inhibited by ICS, there is a proportion of uncontrolled asthma patients who, despite treatment with high-dosage ICS and systemic corticosteroids, have elevated levels of IL-13 in their sputum [141]. Hence, the IL-13 pathway has been identified as a potential therapeutic target in severe asthma and associated allergic diseases, with selective monoclonal antibody therapies being developed. There is a clear need for unified management of these type 2 inflammatory airway diseases.

Targeted therapies

Improved understanding of the type 2 inflammatory mediators described here has led to the development of targeted therapies for upper and lower type 2 inflammatory airway diseases, many of which are yielding promising results in difficult-to-treat asthma patients. The six biological therapies approved for asthma so far, and some other type 2 inflammatory diseases, include omalizumab (anti-IgE), mepolizumab (anti-IL-5), reslizumab (anti–IL-5), benralizumab (anti-IL-5Rα), dupilumab (anti-IL-4Rα) and tezepelumab (anti-thymic stromal lymphopoietin (TSLP)), each of these targeting specific cytokines involved in the type 2 inflammatory cascade (table 4). Omalizumab is approved as an add-on treatment for moderate-to-severe persistent allergic asthma inadequately controlled with ICS and for severe CRSwNP. Omalizumab binds to free circulating IgE [145, 146]; however, because IgE production occurs downstream of Th2 cell activation and IL-4 and IL-13 release, it can only target one feature of the type 2 inflammatory response [147–152]. Three anti-IL-5 therapies (mepolizumab, reslizumab and benralizumab) are approved as add-on agents for the treatment of severe eosinophilic asthma [143, 153–157]. Mepolizumab and reslizumab inhibit IL-5 activity by blocking the binding of IL-5 to the receptor expressed on the eosinophils cell surface, while benralizumab binds directly to IL-5Rα expressed on eosinophils and basophils. Dupilumab is a human monoclonal antibody, which binds specifically to the shared receptor component for IL-4 and IL-13, thus inhibiting the dual signalling pathways of both IL-4 and IL-13 [31]. Thus, dupilumab inhibits IL-4 signalling via the type 1 receptor and both IL-4 and IL-13 signalling through the type 2 receptor.

View this table:
  • View inline
  • View popup
TABLE 4

Approved biological therapies for type 2 inflammatory airway diseases

Each of these targeted biological agents have demonstrated clinical benefits in patients with type 2 inflammatory airway diseases. Two of three pivotal trials of omalizumab, as an add-on to high-dose ICS plus LABA, demonstrated reduced asthma exacerbations in adolescents and adults with moderate-to-severe asthma with an allergic phenotype [145]. However, omalizumab may have limited effects on lung function. Similar results were seen in two trials of mepolizumab in patients selected with raised blood eosinophil levels (Mepolizumab as Adjunctive Therapy in Patients with Severe Asthma (MENSA) and Steroid Reduction with Mepolizumab Study (SIRIUS)), which, despite not showing consistent improvement in lung function across trials, significantly reduced asthma exacerbations as well as improving QoL [158]. However, anti-IL-5 treatment was successful in the MENSA and SIRIUS trials in patients selected for raised blood eosinophil levels. Intravenous reslizumab has also demonstrated significant improvements in lung function, asthma exacerbations [159, 160] and QoL; however, reduction in OCS daily dose was not achieved with the subcutaneous formulation [159, 161]. Similar results were seen in the CALIMA and SIROCCO trials of benralizumab, with beneficial effects on exacerbations, lung function and QoL; however, these benefits were only seen consistently in patients with blood eosinophil count ≥300 cells·μL−1 [162]. A recent study found a significant reduction in exacerbations and reduced need for OCS in patients following 1 year of treatment with benralizumab [163]. Clinical trials of dupilumab demonstrate reduced asthma exacerbations and produced rapid and sustained improvements in lung function, QoL and asthma control in patients with uncontrolled persistent asthma [164–167]. Moreover, dupilumab has enabled reduction in OCS use, regardless of type 2 inflammatory biomarker at baseline, while maintaining reductions in exacerbations and improvements in lung function, QoL and asthma control in a broad population of adults with severe steroid-dependent asthma [168].

In patients with comorbid CRSwNP, mepolizumab has reduced the rate of asthma exacerbations [169, 170]. Similar results have been seen with benralizumab in patients with asthma and comorbid CRSwNP [171]. In patients with eosinophilic asthma and self-reported CRSwNP, after 52 weeks’ reslizumab add-on therapy, asthma exacerbations were reduced by 83% and lung function (FEV1) improved compared with placebo; QoL and Asthma Control Questionnaire score were also reported to have improved in this population of eosinophilic asthma with nasal polyps [172, 173].

There is a comprehensive clinical trials programme of dupilumab in patients with CRSwNP, which has shown that dupilumab provides rapid and continuous improvement in clinical symptoms (e.g. nasal congestion, loss of smell and rhinorrhea), QoL, polyp size and sinus disease in patients uncontrolled on standard of care [174]. Moreover, dupilumab has been shown to reduce the need for systemic corticosteroids and/or the need for sinonasal surgery in adults with severe CRSwNP [175]. Furthermore, clinical trials of dupilumab have demonstrated improvements in patients with asthma and comorbid CRSwNP, including exacerbations, lung function, asthma control and QoL [176–178]. In addition, dupilumab has been shown to allow reduction of OCS dose in this patient cohort [179], and in patients presenting with CRSwNP and comorbid asthma [180]. Trials of each of these biologicals have presented a good and consistent safety profile in patients with type 2 inflammatory airways diseases. In conjunction with clinically meaningful improvement in symptoms, lung function and QoL, as well as reduction in corticosteroid use, biologicals represent an important advance in the management of uncontrolled asthma and comorbid type 2 inflammatory airway diseases.

With a better understanding of asthma pathophysiology, upstream targets of type 2 inflammation have been identified such as alarmins (IL-33 or TSLP) and some emerging biological therapies targeting those epithelial-derived cytokines are under investigation with a need for patients with type 2 low or non-type 2 asthma [181]. More recently, tezepelumab, a TSLP blocker, has been approved by the United States Food and Drug Administration as an add-on maintenance treatment in severe asthma [182].

Conclusions

Effective management of type 2 inflammatory airway diseases represents a major unmet need. Severe asthma continues to outpace asthma control in patients whose disease is managed by LABA and ICS, resulting in significant cost burden and impact on QoL of affected patients. Identifying individuals with comorbidities is important for adequate control of severe type 2 asthma, most notably with novel biological therapies that target the immune biomarkers, such as IL-4, IL-5 and IL-13. A substantial proportion of patients with asthma or severe CRSwNP remain suboptimally controlled with conventional therapies, highlighting the need for new therapies that target disease pathophysiology. Treatment guidelines for the management of asthma and CRSwNP are focused on improving signs and symptoms and achieving disease control. As treatment guidelines continue to acknowledge the value of, and recommend targeted therapies for, the treatment of asthma and comorbid type 2 inflammatory airway diseases, global access to these therapies becomes increasingly important to patients, clinicians, and society. There still remains a need for a unified treatment strategy for patients with coexisting type 2 inflammatory diseases.

Footnotes

  • Provenance: Submitted article, peer reviewed.

  • Conflict of interest: J. Maspero reports grants and personal fees from AstraZeneca, MSD, Novartis, and Sanofi, personal fees from Uriach and Inmunotek, and grants and nonfinancial support from GSK.

  • Conflict of interest: Y. Adir reports personal fees from Teva and Sanofi, and grants and personal fees from GSK and AstraZeneca.

  • Conflict of interest: M. Al-Ahmad has nothing to disclose.

  • Conflict of interest: C. Celis-Preciado reports grants and personal fees from AstraZeneca and GSK, grants from Boehringer, and personal fees from Novartis and Sanofi.

  • Conflict of interest: F.D. Colodenco has nothing to disclose.

  • Conflict of interest: P. Giavina-Bianchi has nothing to disclose.

  • Conflict of interest: H. Lababidi has nothing to disclose.

  • Conflict of interest: O. Ledanois is an employee of Sanofi.

  • Conflict of interest: B. Mahoub has nothing to disclose.

  • Conflict of interest: D-W. Perng has nothing to disclose.

  • Conflict of interest: J.C. Vazquez reports personal fees from AstraZeneca, Boehringer Ingelheim and Sanofi.

  • Conflict of interest: A. Yorgancioglu reports grants/research support from AstraZeneca, MSD, and Sanofi; honoraria/consultation fees from Abdi İbrahim, AstraZeneca, Chiesi, DEVA, GSK, Novartis Sandoz and Sanofi; and other support from ERS, GARD, GINA, Turkish MoH and WHO.

  • Support statement: This publication was supported by Sanofi. Medical writing support was provided by John Clarke (Elevate Medical Affairs (part of Envision Pharma Group), Horsham, UK), contracted by Sanofi Genzyme for publication support services. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received October 22, 2021.
  • Accepted February 22, 2022.
  • Copyright ©The authors 2022
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org

References

  1. ↵
    1. Global Initiative for Asthma.
    Global Strategy for Asthma Management and Prevention. 2019. https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf. Date last accessed: January 2021.
  2. ↵
    1. Fokkens WJ,
    2. Lund VJ,
    3. Hopkins C, et al.
    European position paper on rhinosinusitis and nasal polyps 2020. Rhinology 2020; 58: Suppl. S29, 1–464. doi:10.4193/Rhin20.600
    OpenUrlCrossRefPubMed
  3. ↵
    1. Schleimer RP
    . Immunopathogenesis of chronic rhinosinusitis and nasal polyposis. Annu Rev Pathol 2017; 12: 331–357. doi:10.1146/annurev-pathol-052016-100401
    OpenUrlCrossRefPubMed
  4. ↵
    1. Pinart M,
    2. Benet M,
    3. Annesi-Maesano I, et al.
    Comorbidity of eczema, rhinitis, and asthma in IgE-sensitised and non-IgE-sensitised children in MeDALL: a population-based cohort study. Lancet Respir Med 2014; 2: 131–140. doi:10.1016/S2213-2600(13)70277-7
    OpenUrl
  5. ↵
    1. Lee LK,
    2. Obi E,
    3. Paknis B, et al.
    Asthma control and disease burden in patients with asthma and allergic comorbidities. J Asthma 2018; 55: 208–219. doi:10.1080/02770903.2017.1316394
    OpenUrl
  6. ↵
    1. Porsbjerg C,
    2. Menzies-Gow A
    . Co-morbidities in severe asthma: clinical impact and management. Respirology 2017; 22: 651–661. doi:10.1111/resp.13026
    OpenUrlPubMed
  7. ↵
    1. Kauppi P,
    2. Linna M,
    3. Jantunen J, et al.
    Chronic comorbidities contribute to the burden and costs of persistent asthma. Mediators Inflamm 2015; 2015: 819194. doi:10.1155/2015/819194
    OpenUrl
  8. ↵
    1. Godard P,
    2. Chanez P,
    3. Siraudin L, et al.
    Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002; 19: 61–67. doi:10.1183/09031936.02.00232001
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Hernandez G,
    2. Dima AL,
    3. Pont A, et al.
    Impact of asthma on women and men: comparison with the general population using the EQ-5D-5L questionnaire. PLoS One 2018; 13: e0202624. doi:10.1371/journal.pone.0202624
    OpenUrl
  10. ↵
    1. Kim KH,
    2. Jahan SA,
    3. Kabir E
    . A review on human health perspective of air pollution with respect to allergies and asthma. Environ Int 2013; 59: 41–52. doi:10.1016/j.envint.2013.05.007
    OpenUrlCrossRefPubMed
  11. ↵
    1. Ali FR
    . Does this patient have atopic asthma? Clin Med 2011; 11: 376–380.
    OpenUrlFREE Full Text
  12. ↵
    1. Adams OJ,
    2. von Gunten S
    . Recent advances in experimental allergy. Int Arch Allergy Immunol 2018; 177: 281–289. doi:10.1159/000494440
    OpenUrl
  13. ↵
    1. Center for Disease Control
    . Most Recent Asthma Data. www.cdc.gov/asthma/most_recent_data.htm/ Date last accessed: January 2021.
  14. ↵
    1. Hastan D,
    2. Fokkens WJ,
    3. Bachert C, et al.
    Chronic rhinosinusitis in Europe – an underestimated disease. A GA2LEN study. Allergy 2011; 66: 1216–1223. doi:10.1111/j.1398-9995.2011.02646.x
    OpenUrlCrossRefPubMed
  15. ↵
    1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators
    . Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1211–1259. doi:10.1016/S0140-6736(17)32154-2
    OpenUrlCrossRefPubMed
  16. ↵
    1. Fokkens WJ,
    2. Lund V,
    3. Bachert C, et al.
    EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy 2019; 74: 2312–2319. doi:10.1111/all.13875
    OpenUrl
  17. ↵
    1. Casanova C,
    2. Celli BR,
    3. de-Torres JP, et al.
    Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur Respir J 2017; 50: 1701162. doi:10.1183/13993003.01162-2017
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Singh D,
    2. Kolsum U,
    3. Brightling CE, et al.
    Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J 2014; 44: 1697–1700. doi:10.1183/09031936.00162414
    OpenUrlFREE Full Text
  19. ↵
    1. European Academy of Allergy and Clinical Immunology (EAACI)
    . EAACI Global Atlas of Allergic Rhinitis and Chronic Rhinosinusitis. 2015. Available from: https://medialibrary.eaaci.org/mediatheque/media.aspx?mediaId=60232&channel=8518
  20. ↵
    1. Corren J,
    2. Lemanske RF,
    3. Hanania NA, et al.
    Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088–1098. doi:10.1056/NEJMoa1106469
    OpenUrlCrossRefPubMed
    1. Schleich F,
    2. Brusselle G,
    3. Louis R, et al.
    Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med 2014; 108: 1723–1732. doi:10.1016/j.rmed.2014.10.007
    OpenUrlCrossRefPubMed
  21. ↵
    1. Peters MC,
    2. Mekonnen ZK,
    3. Yuan S, et al.
    Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol 2014; 133: 388–394. doi:10.1016/j.jaci.2013.07.036
    OpenUrlCrossRef
  22. ↵
    1. Kim DW,
    2. Cho SH
    . Emerging endotypes of chronic rhinosinusitis and its application to precision medicine. Allergy Asthma Immunol Res 2017; 9: 299–306. doi:10.4168/aair.2017.9.4.299
    OpenUrl
  23. ↵
    1. Bachert C,
    2. Pawankar R,
    3. Zhang L, et al.
    ICON: chronic rhinosinusitis. World Allergy Organ J 2014; 7: 25. doi:10.1186/1939-4551-7-25
    OpenUrl
  24. ↵
    1. Delemarre T,
    2. Holtappels G,
    3. De Ruyck N, et al.
    Type 2 inflammation in chronic rhinosinusitis without nasal polyps: another relevant endotype. J Allergy Clin Immunol 2020; 146: 337–343. doi:10.1016/j.jaci.2020.04.040
    OpenUrl
  25. ↵
    1. Khan A,
    2. Vandeplas G,
    3. Huynh TMT, et al.
    The Global Allergy and Asthma European Network (GALEN) rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology 2019; 57: 32–42. doi:10.4193/Rhin17.255
    OpenUrl
    1. Bousquet J,
    2. Khaltaev N,
    3. Cruz AA, et al.
    Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy 2008; 63: Suppl. 86, 8–160. doi:10.1111/j.1398-9995.2007.01620.x
    OpenUrlCrossRefPubMed
    1. Mindus S,
    2. Malinovschi A,
    3. Ekerljung L, et al.
    Asthma and COPD overlap (ACO) is related to a high burden of sleep disturbance and respiratory symptoms: results from the RHINE and Swedish GA2LEN surveys. PLoS One 2018; 13: e0195055. doi:10.1371/journal.pone.0195055
    OpenUrl
  26. ↵
    1. White AA,
    2. Stevenson DD
    . Aspirin-exacerbated respiratory disease. N Engl J Med 2018; 379: 1060–1070. doi:10.1056/NEJMra1712125
    OpenUrlCrossRefPubMed
  27. ↵
    1. Shaw DE,
    2. Sousa AR,
    3. Fowler SJ, et al.
    Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J 2015; 46: 1308–1321. doi:10.1183/13993003.00779-2015
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Gandhi NA,
    2. Bennett BL,
    3. Graham NM, et al.
    Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 2016; 15: 35–50. doi:10.1038/nrd4624
    OpenUrlCrossRefPubMed
    1. Heffler E,
    2. Blasi F,
    3. Latorre M, et al.
    The Severe Asthma Network in Italy: findings and perspectives. J Allergy Clin Immunol Pract 2019; 7: 1462–1468. doi:10.1016/j.jaip.2018.10.016
    OpenUrl
    1. Maio S,
    2. Baldacci S,
    3. Bresciani M, et al.
    RItA: the Italian severe/uncontrolled asthma registry. Allergy 2018; 73: 683–695. doi:10.1111/all.13342
    OpenUrl
    1. Micheletto C,
    2. Visconti M,
    3. Trevisan F, et al.
    The prevalence of nasal polyps and the corresponding urinary LTE4 levels in severe compared to mild and moderate asthma. Eur Ann Allergy Clin Immunol 2010; 42: 120–124.
    OpenUrlPubMed
    1. Miravitlles M,
    2. Alvarez-Gutierrez FJ,
    3. Calle M, et al.
    Algorithm for identification of asthma-COPD overlap: consensus between the Spanish COPD and asthma guidelines. Eur Respir J 2017; 49: 1700068. doi:10.1183/13993003.00068-2017
    OpenUrlAbstract/FREE Full Text
    1. Toledo-Pons N,
    2. van Boven JFM,
    3. Roman-Rodríguez M, et al.
    ACO: time to move from the description of different phenotypes to the treatable traits. PLoS One 2019; 14: e0210915. doi:10.1371/journal.pone.0210915
    OpenUrl
    1. Licari A,
    2. Castagnoli R,
    3. Denicolò CF, et al.
    The nose and the lung: united airway disease? Front Pediatr 2017; 5: 44. doi:10.3389/fped.2017.00044
    OpenUrl
    1. Sahay S,
    2. Gera K,
    3. Bhargava SK, et al.
    Occurrence and impact of sinusitis in patients with asthma and/or allergic rhinitis. J Asthma 2016; 53: 635–643. doi:10.3109/02770903.2015.1091005
    OpenUrl
    1. Jackson D,
    2. Aljamil N,
    3. Roxas C, et al.
    The ‘T2-low’ asthma phenotype: could it just be T2-high asthma treated with corticosteroids? Thorax 2018; 73: A124–A125. doi:10.1136/thorax-2018-212555.206
    OpenUrl
    1. Kato A,
    2. Klingler AI,
    3. Stevens WW, et al.
    Heterogenous inflammation in chronic rhinosinusitis without nasal polyps. J Allergy Clin Immunol 2016; 137: AB285. doi:10.1016/j.jaci.2015.12.1180
    OpenUrl
  29. ↵
    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD)
    . Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2019. https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf Date last accessed: January 2021.
    1. Håkansson K,
    2. Konge L,
    3. Thomsen SF, et al.
    Sinonasal inflammation in COPD: a systematic review. Eur Respir J 2013; 42: 1402–1411. doi:10.1183/09031936.00119712
    OpenUrlAbstract/FREE Full Text
    1. Øie MR,
    2. Dahlslett SB,
    3. Sue-Chu M, et al.
    Rhinosinusitis without nasal polyps in COPD. ERJ Open Res 2020; 6: 00015-2020. doi:10.1183/23120541.00015-2020
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Dean BB,
    2. Calimlim BM,
    3. Kindermann SL, et al.
    The impact of uncontrolled asthma on absenteeism and health-related quality of life. J Asthma 2009; 46: 861–866. doi:10.3109/02770900903184237
    OpenUrlCrossRefPubMed
  31. ↵
    1. Sanz de Burgoa V,
    2. Rejas J
    . Self-perceived sleep quality and quantity in adults with asthma: findings from the CosteAsma study. J Investig Allergol Clin Immunol 2016; 26: 256–262. doi:10.18176/jiaci.0044
    OpenUrl
    1. Serrano E,
    2. Neukirch F,
    3. Pribil C, et al.
    Nasal polyposis in France: impact on sleep and quality of life. J Laryngol Otol 2005; 119: 543–549. doi:10.1258/0022215054352108
    OpenUrlPubMed
  32. ↵
    1. Radenne F,
    2. Lamblin C,
    3. Vandezande LM, et al.
    Quality of life in nasal polyposis. J Allergy Clin Immunol 1999; 104: 79–84. doi:10.1016/S0091-6749(99)70117-X
    OpenUrlCrossRefPubMed
  33. ↵
    1. Price D,
    2. Fletcher M,
    3. van der Molen T
    . Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med 2014; 24: 14009. doi:10.1038/npjpcrm.2014.9
    OpenUrlCrossRefPubMed
  34. ↵
    1. Sullivan PW,
    2. Ghushchyan VH,
    3. Globe G, et al.
    Oral corticosteroid exposure and adverse effects in asthmatic patients. J Allergy Clin Immunol 2018; 141: 110–116. doi:10.1016/j.jaci.2017.04.009
    OpenUrlCrossRefPubMed
  35. ↵
    1. Boulet LP
    . Influence of comorbid conditions on asthma. Eur Respir J 2009; 33: 897–906. doi:10.1183/09031936.00121308
    OpenUrlAbstract/FREE Full Text
    1. Ponte EV,
    2. Franco R,
    3. Nascimento HF, et al.
    Lack of control of severe asthma is associated with co-existence of moderate-to-severe rhinitis. Allergy 2008; 63: 564–569. doi:10.1111/j.1398-9995.2007.01624.x
    OpenUrlCrossRefPubMed
    1. Staiküniene J,
    2. Vaitkus S,
    3. Japertiene LM, et al.
    Association of chronic rhinosinusitis with nasal polyps and asthma: clinical and radiological features, allergy and inflammation markers. Medicina 2008; 44: 257–265. doi:10.3390/medicina44040033
    OpenUrl
  36. ↵
    1. Stevens WW,
    2. Peters AT,
    3. Hirsch AG, et al.
    Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract 2017; 5: 1061–1070. doi:10.1016/j.jaip.2016.12.027
    OpenUrl
  37. ↵
    1. Vietri J,
    2. Burslem K,
    3. Su J
    . Poor asthma control among US workers: health-related quality of life, work impairment, and health care use. J Occup Environ Med 2014; 56: 425–430. doi:10.1097/JOM.0000000000000123
    OpenUrl
  38. ↵
    1. Williams SA,
    2. Wagner S,
    3. Kannan H, et al.
    The association between asthma control and health care utilization, work productivity loss and health-related quality of life. J Occup Environ Med 2009; 51: 780–785. doi:10.1097/JOM.0b013e3181abb019
    OpenUrlCrossRefPubMed
  39. ↵
    1. Hossny E,
    2. Caraballo L,
    3. Casale T, et al.
    Severe asthma and quality of life. World Allergy Organ J 2017; 10: 28. doi:10.1186/s40413-017-0159-y
    OpenUrl
  40. ↵
    1. ten Brinke A,
    2. Sterk PJ,
    3. Masclee AA, et al.
    Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J 2005; 26: 812–818. doi:10.1183/09031936.05.00037905
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Chung KF,
    2. Wenzel SE,
    3. Brozek JL, et al.
    International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343–373. doi:10.1183/09031936.00202013
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Tay TR,
    2. Hew M
    . Comorbid “treatable traits” in difficult asthma: current evidence and clinical evaluation. Allergy 2018; 73: 1369–1382. doi:10.1111/all.13370
    OpenUrl
    1. Auckley D,
    2. Moallem M,
    3. Shaman Z, et al.
    Findings of a Berlin Questionnaire survey: comparison between patients seen in an asthma clinic versus internal medicine clinic. Sleep Med 2008; 9: 494–499. doi:10.1016/j.sleep.2007.06.010
    OpenUrlCrossRefPubMed
    1. de Carvalho-Pinto RM,
    2. Cukier A,
    3. Angelini L, et al.
    Clinical characteristics and possible phenotypes of an adult severe asthma population. Respir Med 2012; 106: 47–56. doi:10.1016/j.rmed.2011.08.013
    OpenUrlCrossRefPubMed
    1. Moore WC,
    2. Bleecker ER,
    3. Curran-Everett D, et al.
    Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119: 405–413. doi:10.1016/j.jaci.2006.11.639
    OpenUrlCrossRefPubMed
  43. ↵
    1. Moore WC,
    2. Meyers DA,
    3. Wenzel SE, et al.
    Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181: 315–323. doi:10.1164/rccm.200906-0896OC
    OpenUrlCrossRefPubMed
    1. Stanton AE,
    2. Vaughn P,
    3. Carter R, et al.
    An observational investigation of dysfunctional breathing and breathing control therapy in a problem asthma clinic. J Asthma 2008; 45: 758–765. doi:10.1080/02770900802252093
    OpenUrlCrossRefPubMed
  44. ↵
    1. Yelken K,
    2. Yilmaz A,
    3. Guven M, et al.
    Paradoxical vocal fold motion dysfunction in asthma patients. Respirology 2009; 14: 729–733. doi:10.1111/j.1440-1843.2009.01568.x
    OpenUrlPubMed
  45. ↵
    1. Ek A,
    2. Middelveld RJ,
    3. Bertilsson H, et al.
    Chronic rhinosinusitis in asthma is a negative predictor of quality of life: results from the Swedish GA2LEN survey. Allergy 2013; 68: 1314–1321. doi:10.1111/all.12222
    OpenUrlCrossRefPubMed
  46. ↵
    1. Liou A,
    2. Grubb JR,
    3. Schechtman KB, et al.
    Causative and contributive factors to asthma severity and patterns of medication use in patients seeking specialized asthma care. Chest 2003; 124: 1781–1788. doi:10.1378/chest.124.5.1781
    OpenUrlCrossRefPubMed
  47. ↵
    1. ten Brinke A,
    2. Grootendorst DC,
    3. Schmidt JT, et al.
    Chronic sinusitis in severe asthma is related to sputum eosinophilia. J Allergy Clin Immunol 2002; 109: 621–626. doi:10.1067/mai.2002.122458
    OpenUrlCrossRefPubMed
  48. ↵
    1. Ceylan E,
    2. Gencer M,
    3. San I
    . Nasal polyps and the severity of asthma. Respirology 2007; 12: 272–276. doi:10.1111/j.1440-1843.2006.00964.x
    OpenUrlCrossRefPubMed
  49. ↵
    1. Hulse KE
    . Immune mechanisms of chronic rhinosinusitis. Curr Allergy Asthma Rep 2016; 16: 1. doi:10.1007/s11882-015-0579-0
    OpenUrlCrossRefPubMed
  50. ↵
    1. Boita M,
    2. Bucca C,
    3. Riva G, et al.
    Release of type 2 cytokines by epithelial cells of nasal polyps. J Immunol Res 2016; 2016: 2643297. doi:10.1155/2016/2643297
    OpenUrl
  51. ↵
    1. Tomassen P,
    2. Vandeplas G,
    3. Van Zele T, et al.
    Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol 2016; 137: 1449–1456. doi:10.1016/j.jaci.2015.12.1324
    OpenUrlCrossRefPubMed
  52. ↵
    1. Bachert C,
    2. Zhang L,
    3. Gevaert P
    . Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis. J Allergy Clin Immunol 2015; 136: 1431–1440. doi:10.1016/j.jaci.2015.10.010
    OpenUrlPubMed
  53. ↵
    1. Jarvis D,
    2. Newson R,
    3. Lotvall J, et al.
    Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. Allergy 2012; 67: 91–98. doi:10.1111/j.1398-9995.2011.02709.x
    OpenUrlCrossRefPubMed
  54. ↵
    1. Bilodeau L,
    2. Boulay ME,
    3. Prince P, et al.
    Comparative clinical and airway inflammatory features of asthmatics with or without polyps. Rhinology 2010; 48: 420–425. doi:10.4193/Rhino09.095
    OpenUrlPubMed
  55. ↵
    1. Vandenplas O,
    2. Dramaix M,
    3. Joos G, et al.
    The impact of concomitant rhinitis on asthma-related quality of life and asthma control. Allergy 2010; 65: 1290–1297. doi:10.1111/j.1398-9995.2010.02365.x
    OpenUrlCrossRefPubMed
  56. ↵
    1. Bassiouni A,
    2. Wormald PJ
    . Role of frontal sinus surgery in nasal polyp recurrence. Laryngoscope 2013; 123: 36–41. doi:10.1002/lary.23610
    OpenUrl
  57. ↵
    1. Coumou H,
    2. Westerhof GA,
    3. de Nijs SB, et al.
    Predictors of accelerated decline in lung function in adult-onset asthma. Eur Respir J 2018; 51: 1701785. doi:10.1183/13993003.01785-2017
    OpenUrlAbstract/FREE Full Text
  58. ↵
    1. Blakey JD,
    2. Price DB,
    3. Pizzichini E, et al.
    Identifying risk of future asthma attacks using UK medical record data: a Respiratory Effectiveness Group initiative. J Allergy Clin Immunol Pract 2017; 5: 1015–1024. doi:10.1016/j.jaip.2016.11.007
    OpenUrl
  59. ↵
    1. Braido F,
    2. Baiardini I,
    3. Ghiglione V, et al.
    Sleep disturbances and asthma control: a real life study. Asian Pac J Allergy Immunol 2009; 27: 27–33.
    OpenUrlPubMed
  60. ↵
    1. Alobid I,
    2. Benítez P,
    3. Bernal-Sprekelsen M, et al.
    Nasal polyposis and its impact on quality of life: comparison between the effects of medical and surgical treatments. Allergy 2005; 60: 452–458. doi:10.1111/j.1398-9995.2005.00725.x
    OpenUrlCrossRefPubMed
    1. Alobid I,
    2. Benítez P,
    3. Valero A, et al.
    The impact of atopy, sinus opacification, and nasal patency on quality of life in patients with severe nasal polyposis. Otolaryngol Head Neck Surg 2006; 134: 609–612. doi:10.1016/j.otohns.2005.10.061
    OpenUrlCrossRefPubMed
  61. ↵
    1. Demoly P,
    2. Annunziata K,
    3. Gubba E, et al.
    Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur Respir Rev 2012; 21: 66–74. doi:10.1183/09059180.00008111
    OpenUrlAbstract/FREE Full Text
  62. ↵
    1. Lange P,
    2. Çolak Y,
    3. Ingebrigtsen TS, et al.
    Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen City Heart study: a prospective population-based analysis. Lancet Respir Med 2016; 4: 454–462. doi:10.1016/S2213-2600(16)00098-9
    OpenUrl
  63. ↵
    1. Rudmik L,
    2. Soler ZM
    . Medical therapies for adult chronic sinusitis: a systematic review. JAMA 2015; 314: 926–939. doi:10.1001/jama.2015.7544
    OpenUrlCrossRefPubMed
  64. ↵
    1. Cooper V,
    2. Metcalf L,
    3. Versnel J, et al.
    Patient-reported side effects, concerns and adherence to corticosteroid treatment for asthma, and comparison with physician estimates of side-effect prevalence: a UK-wide, cross-sectional study. NPJ Prim Care Respir Med 2015; 25: 15026. doi:10.1038/npjpcrm.2015.26
    OpenUrlCrossRefPubMed
  65. ↵
    1. Canonica GW,
    2. Colombo GL,
    3. Bruno GM, et al.
    Shadow cost of oral corticosteroids-related adverse events: a pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry. World Allergy Organ J 2019; 12: 100007. doi:10.1016/j.waojou.2018.12.001
    OpenUrl
  66. ↵
    1. Bhattacharyya N,
    2. Villeneuve S,
    3. Joish VN, et al.
    Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps. Laryngoscope 2019; 129: 1969–1975. doi:10.1002/lary.27852
    OpenUrlPubMed
  67. ↵
    1. Gaugris S,
    2. Sazonov-Kocevar V,
    3. Thomas M
    . Burden of concomitant allergic rhinitis in adults with asthma. J Asthma 2006; 43: 1–7. doi:10.1080/02770900500446823
    OpenUrlCrossRefPubMed
  68. ↵
    1. Chung KF
    . Targeting the interleukin pathway in the treatment of asthma. Lancet 2015; 386: 1086–1096. doi:10.1016/S0140-6736(15)00157-9
    OpenUrlCrossRefPubMed
  69. ↵
    1. Fahy JV
    . Type 2 inflammation in asthma – present in most, absent in many. Nat Rev Immunol 2015; 15: 57–65. doi:10.1038/nri3786
    OpenUrlCrossRefPubMed
  70. ↵
    1. Gandhi NA,
    2. Pirozzi G,
    3. Graham NMH
    . Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol 2017; 13: 425–437. doi:10.1080/1744666X.2017.1298443
    OpenUrl
  71. ↵
    1. Robinson D,
    2. Humbert M,
    3. Buhl R, et al
    . Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy 2017; 47: 161–175. http://dx.doi.org/10.1111/cea.12880
    OpenUrlCrossRef
    1. Corren J
    . Role of interleukin-13 in asthma. Curr Allergy Asthma Rep 2013; 13: 415–420. doi:10.1007/s11882-013-0373-9
    OpenUrlCrossRefPubMed
    1. Fulkerson PC,
    2. Rothenberg ME
    . Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov 2013; 12: 117–129. doi:10.1038/nrd3838
    OpenUrlCrossRefPubMed
    1. Le Floc’h A,
    2. Allinne J,
    3. Nagashima K, et al
    . Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy 2020; 75: 1188–1204. http://dx.doi.org/10.1111/all.v75.5
    OpenUrlCrossRef
    1. Kato A
    . Immunopathology of chronic rhinosinusitis. Allergol Int 2015; 64: 121–130. doi:10.1016/j.alit.2014.12.006
    OpenUrlCrossRefPubMed
    1. Ramanathan M Jr.,
    2. Lee WK,
    3. Spannhake EW, et al.
    Th2 cytokines associated with chronic rhinosinusitis with polyps down-regulate the antimicrobial immune function of human sinonasal epithelial cells. Am J Rhinol 2008; 22: 115–121. doi:10.2500/ajr.2008.22.3136
    OpenUrlCrossRefPubMed
  72. ↵
    1. Wise SK,
    2. Laury AM,
    3. Katz EH, et al.
    Interleukin-4 and interleukin-13 compromise the sinonasal epithelial barrier and perturb intercellular junction protein expression. Int Forum Allergy Rhinol 2014; 4: 361–370. doi:10.1002/alr.21298
    OpenUrl
  73. ↵
    1. Ahern S,
    2. Cervin A
    . Inflammation and endotyping in chronic rhinosinusitis – a paradigm shift. Medicina 2019; 55: 95. doi:10.3390/medicina55040095
    OpenUrl
    1. Kato A
    . Group 2 innate lymphoid cells in airway diseases. Chest 2019; 156: 141–149. doi:10.1016/j.chest.2019.04.101
    OpenUrlCrossRef
  74. ↵
    1. Naik SR,
    2. Wala SM
    . Inflammation, allergy and asthma, complex immune origin diseases: mechanisms and therapeutic agents. Recent Pat Inflamm Allergy Drug Discov 2013; 7: 62–95. doi:10.2174/187221313804004682
    OpenUrl
  75. ↵
    1. Kuruvilla ME,
    2. Lee FE,
    3. Lee GB
    . Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol 2019; 56: 219–233. doi:10.1007/s12016-018-8712-1
    OpenUrlPubMed
  76. ↵
    1. Dunican EM,
    2. Elicker BM,
    3. Gierada DS, et al.
    Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J Clin Invest 2018; 128: 997–1009. doi:10.1172/JCI95693
    OpenUrlCrossRefPubMed
  77. ↵
    1. Israel E,
    2. Reddel HK
    . Severe and difficult-to-treat asthma in adults. N Engl J Med 2017; 377: 965–976. doi:10.1056/NEJMra1608969
    OpenUrlCrossRefPubMed
  78. ↵
    1. McLeod JJ,
    2. Baker B,
    3. Ryan JJ
    . Mast cell production and response to IL-4 and IL-13. Cytokine 2015; 75: 57–61. doi:10.1016/j.cyto.2015.05.019
    OpenUrlCrossRef
  79. ↵
    1. Kaur D,
    2. Hollins F,
    3. Woodman L, et al.
    Mast cells express IL-13Rα1: IL-13 promotes human lung mast cell proliferation and FcεRI expression. Allergy 2006; 61: 1047–1053. doi:10.1111/j.1398-9995.2006.01139.x
    OpenUrlCrossRefPubMed
  80. ↵
    1. Bonser LR,
    2. Zlock L,
    3. Finkbeiner W, et al.
    Epithelial tethering of MUC5AC-rich mucus impairs mucociliary transport in asthma. J Clin Invest 2016; 126: 2367–2371. doi:10.1172/JCI84910
    OpenUrlCrossRef
  81. ↵
    1. Suresh V,
    2. Mih JD,
    3. George SC
    . Measurement of IL-13-induced iNOS-derived gas phase nitric oxide in human bronchial epithelial cells. Am J Respir Cell Mol Biol 2007; 37: 97–104. doi:10.1165/rcmb.2006-0419OC
    OpenUrlCrossRefPubMed
  82. ↵
    1. Saatian B,
    2. Rezaee F,
    3. Desando S, et al.
    Interleukin-4 and interleukin-13 cause barrier dysfunction in human airway epithelial cells. Tissue Barriers 2013; 1: e24333. doi:10.4161/tisb.24333
    OpenUrl
  83. ↵
    1. Mauad T,
    2. Bel EH,
    3. Sterk PJ
    . Asthma therapy and airway remodeling. J Allergy Clin Immunol 2007; 120: 997–1009. doi:10.1016/j.jaci.2007.06.031
    OpenUrlCrossRefPubMed
    1. Ishida A,
    2. Ohta N,
    3. Suzuki Y, et al.
    Expression of pendrin and periostin in allergic rhinitis and chronic rhinosinusitis. Allergol Int 2012; 61: 589–595. doi:10.2332/allergolint.11-OA-0370
    OpenUrlCrossRefPubMed
  84. ↵
    1. Gudis D,
    2. Zhao KQ,
    3. Cohen NA
    . Acquired cilia dysfunction in chronic rhinosinusitis. Am J Rhinol Allergy 2012; 26: 1–6. doi:10.2500/ajra.2012.26.3716
    OpenUrlCrossRefPubMed
  85. ↵
    1. Takabayashi T,
    2. Kato A,
    3. Peters AT, et al.
    Excessive fibrin deposition in nasal polyps caused by fibrinolytic impairment through reduction of tissue plasminogen activator expression. Am J Respir Crit Care Med 2013; 187: 49–57. doi:10.1164/rccm.201207-1292OC
    OpenUrlCrossRefPubMed
  86. ↵
    1. Liu J,
    2. Li YY,
    3. Andiappan AK, et al.
    Role of IL-13Rα2 in modulating IL-13-induced MUC5AC and ciliary changes in healthy and CRSwNP mucosa. Allergy 2018; 73: 1673–1685. doi:10.1111/all.13424
    OpenUrl
  87. ↵
    1. Holgate ST,
    2. Polosa R
    . The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006; 368: 780–793. doi:10.1016/S0140-6736(06)69288-X
    OpenUrlCrossRefPubMed
    1. Schleimer RP,
    2. Berdnikovs S
    . Etiology of epithelial barrier dysfunction in patients with type 2 inflammatory diseases. J Allergy Clin Immunol 2017; 139: 1752–1761. doi:10.1016/j.jaci.2017.04.010
    OpenUrlCrossRef
  88. ↵
    1. Fehrenbach H,
    2. Wagner C,
    3. Wegmann M
    . Airway remodeling in asthma: what really matters. Cell Tissue Res 2017; 367: 551–569. doi:10.1007/s00441-016-2566-8
    OpenUrlCrossRefPubMed
  89. ↵
    1. Lee CG,
    2. Homer RJ,
    3. Zhu Z, et al.
    Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor β1. J Exp Med 2001; 194: 809–821. doi:10.1084/jem.194.6.809
    OpenUrlAbstract/FREE Full Text
  90. ↵
    1. Verbruggen K,
    2. Van Cauwenberge P,
    3. Bachert C
    . Anti-IgE for the treatment of allergic rhinitis – and eventually nasal polyps? Int Arch Allergy Immunol 2009; 148: 87–98. doi:10.1159/000155739
    OpenUrlCrossRefPubMed
    1. Amin K
    . The role of mast cells in allergic inflammation. Respir Med 2012; 106: 9–14. doi:10.1016/j.rmed.2011.09.007
    OpenUrlCrossRefPubMed
  91. ↵
    1. Poole JA,
    2. Rosenwasser LJ
    . The role of immunoglobulin E and immune inflammation: implications in allergic rhinitis. Curr Allergy Asthma Rep 2005; 5: 252–258. doi:10.1007/s11882-005-0045-5
    OpenUrlPubMed
  92. ↵
    1. Agarwal R,
    2. Chakrabarti A,
    3. Shah A, et al.
    Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 2013; 43: 850–873. doi:10.1111/cea.12141
    OpenUrlCrossRefPubMed
  93. ↵
    1. Bantz SK,
    2. Zhu Z,
    3. Zheng T
    . The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. J Clin Cell Immunol 2014; 5: 202. doi:10.4172/2155-9899.1000202
    OpenUrlPubMed
  94. ↵
    1. van der Hulst AE,
    2. Klip H,
    3. Brand PL
    . Risk of developing asthma in young children with atopic eczema: a systematic review. J Allergy Clin Immunol 2007; 120: 565–569. doi:10.1016/j.jaci.2007.05.042
    OpenUrlCrossRefPubMed
  95. ↵
    1. Cai F,
    2. Hornauer H,
    3. Peng K, et al.
    Bioanalytical challenges and improved detection of circulating levels of IL-13. Bioanalysis 2016; 8: 323–332. doi:10.4155/bio.15.254
    OpenUrl
  96. ↵
    1. Greenberger PA,
    2. Bush RK,
    3. Demain JG, et al.
    Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract 2014; 2: 703–708. doi:10.1016/j.jaip.2014.08.007
    OpenUrl
  97. ↵
    1. Kowalski ML,
    2. Agache I,
    3. Bavbek S, et al.
    Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD) – a EAACI position paper. Allergy 2019; 74: 28–39. doi:10.1111/all.13599
    OpenUrl
  98. ↵
    1. Tariq SM,
    2. Matthews SM,
    3. Hakim EA, et al.
    Egg allergy in infancy predicts respiratory allergic disease by 4 years of age. Pediatr Allergy Immunol 2000; 11: 162–167. doi:10.1034/j.1399-3038.2000.00077.x
    OpenUrlCrossRefPubMed
  99. ↵
    1. Emons JAM,
    2. Gerth van Wijk R
    . Food allergy and asthma: is there a link? Curr Treat Options Allergy 2018; 5: 436–444. doi:10.1007/s40521-018-0185-1
    OpenUrl
  100. ↵
    1. Hulse KE,
    2. Stevens WW,
    3. Tan BK, et al.
    Pathogenesis of nasal polyposis. Clin Exp Allergy 2015; 45: 328–346. doi:10.1111/cea.12472
    OpenUrlPubMed
    1. Stevens WW,
    2. Ocampo CJ,
    3. Berdnikovs S, et al.
    Cytokines in chronic rhinosinusitis. Role in eosinophilia and aspirin-exacerbated respiratory disease. Am J Respir Crit Care Med 2015; 192: 682–694. doi:10.1164/rccm.201412-2278OC
    OpenUrlPubMed
    1. Zhai GT,
    2. Li JX,
    3. Zhang XH, et al.
    Increased accumulation of CD30 ligand-positive mast cells associates with eosinophilic inflammation in nasal polyps. Laryngoscope 2019; 129: E110–E117. doi:10.1002/lary.27658
    OpenUrl
  101. ↵
    1. Gause WC,
    2. Wynn TA,
    3. Allen JE
    . Type 2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths. Nat Rev Immunol 2013; 13: 607–614. doi:10.1038/nri3476
    OpenUrlCrossRefPubMed
  102. ↵
    1. Bagnasco D,
    2. Ferrando M,
    3. Varricchi G, et al.
    A critical evaluation of anti-IL-13 and anti-IL-4 strategies in severe asthma. Int Arch Allergy Immunol 2016; 170: 122–131. doi:10.1159/000447692
    OpenUrlCrossRef
  103. ↵
    1. van der Veen J,
    2. Seys SF,
    3. Timmermans M, et al.
    Real-life study showing uncontrolled rhinosinusitis after sinus surgery in a tertiary referral centre. Allergy 2017; 72: 282–290. doi:10.1111/all.12983
    OpenUrl
  104. ↵
    1. Bateman ED,
    2. Boushey HA,
    3. Bousquet J, et al.
    Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 2004; 170: 836–844. doi:10.1164/rccm.200401-033OC
    OpenUrlCrossRefPubMed
  105. ↵
    1. Huscher D,
    2. Thiele K,
    3. Gromnica-Ihle E, et al.
    Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009; 68: 1119–1124. doi:10.1136/ard.2008.092163
    OpenUrlAbstract/FREE Full Text
  106. ↵
    1. Ververeli K,
    2. Chipps B
    . Oral corticosteroid-sparing effects of inhaled corticosteroids in the treatment of persistent and acute asthma. Ann Allergy Asthma Immunol 2004; 92: 512–522. doi:10.1016/S1081-1206(10)61758-9
    OpenUrlCrossRefPubMed
  107. ↵
    1. Orlandi RR,
    2. Kingdom TT,
    3. Hwang PH, et al.
    International consensus statement on allergy and rhinology: rhinosinusitis. Int Forum Allergy Rhinol 2016; 6: Suppl. 1, S22–S209. doi:10.1002/alr.21695
    OpenUrlCrossRefPubMed
  108. ↵
    1. Saha SK,
    2. Berry MA,
    3. Parker D, et al.
    Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol 2008; 121: 685–691. doi:10.1016/j.jaci.2008.01.005
    OpenUrlCrossRefPubMed
    1. Sanofi
    . Dupixent (Dupilumab) Summary of Product Characteristics. 2021. https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf Date last accessed: 1 February 2022.
  109. ↵
    1. GlaxoSmithKline
    . Nucala (Mepolizumab) Summary of Product Characteristcs. September 2019. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF Date last accessed: 1 February 2022.
    1. AstraZeneca
    . A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) (COURSE). https://clinicaltrials.gov/ct2/show/NCT04039113?cond=NCT04039113&draw=2&rank=1 Date last accessed: 1 February 2022.
  110. ↵
    1. Novartis
    . Xolair (Omalizumab) Summary of Product Characteristics. 2019. www.ema.europa.eu/en/documents/product-information/xolair-epar-product-information_en.pdf Date last accessed: January 2021.
  111. ↵
    1. Holgate ST,
    2. Church MK,
    3. Broide DH, et al.
    1. Oettgen H,
    2. Broide DH
    . Introduction to mechanisms of allergic disease. In: Holgate ST, Church MK, Broide DH, et al., eds. Allergy. 4th Edn. New York, Elsevier Saunders, 2012; pp. 1–32.
  112. ↵
    1. Defrance T,
    2. Carayon P,
    3. Billian G, et al.
    Interleukin 13 is a B cell stimulating factor. J Exp Med 1994; 179: 135–143. doi:10.1084/jem.179.1.135
    OpenUrlAbstract/FREE Full Text
    1. Kühn R,
    2. Rajewsky K,
    3. Müller W
    . Generation and analysis of interleukin-4 deficient mice. Science 1991; 254: 707–710. doi:10.1126/science.1948049
    OpenUrlAbstract/FREE Full Text
    1. Pène J,
    2. Rousset F,
    3. Brière F, et al.
    IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons γ and α and prostaglandin E2. Proc Natl Acad Sci USA 1988; 85: 6880–6884. doi:10.1073/pnas.85.18.6880
    OpenUrlAbstract/FREE Full Text
    1. Punnonen J,
    2. Aversa G,
    3. Cocks BG, et al.
    Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci USA 1993; 90: 3730–3734. doi:10.1073/pnas.90.8.3730
    OpenUrlAbstract/FREE Full Text
    1. Finkelman FD,
    2. Urban JF Jr.,
    3. Beckmann MP, et al.
    Regulation of murine in vivo IgG and IgE responses by a monoclonal anti-IL-4 receptor antibody. Int Immunol 1991; 3: 599–607. doi:10.1093/intimm/3.6.599
    OpenUrlCrossRefPubMed
  113. ↵
    1. Yanagihara Y,
    2. Ikizawa K,
    3. Kajiwara K, et al.
    Functional significance of IL-4 receptor on B cells in IL-4-induced human IgE production. J Allergy Clin Immunol 1995; 96: 1145–1151. doi:10.1016/S0091-6749(95)70199-0
    OpenUrlCrossRefPubMed
  114. ↵
    1. GlaxoSmithKline
    . Nucala (Mepolizumab) Summary of Product Characteristics. www.ema.europa.eu/en/documents/product-information/nucala-epar-product-information_en.pdf Date last accessed: January 2021.
    1. Teva Respiratory
    . Cinqair (Reslizumab) Prescribing Information. 2016. www.accessdata.fda.gov/drugsatfda_docs/label/2016/761033lbl.pdf Date last accessed: January 2021.
    1. Teva Pharmaceuticals
    . Cinqaero (Reslizumab) Summary of Product Characteristics. 2017. https://ec.europa.eu/health/documents/community-register/2017/20170428137621/anx_137621_en.pdf Date last accessed: January 2021.
    1. AstraZeneca Pharmaceuticals
    . Fasenra (Benralizumab) Prescribing Information. 2021. Available from: https://medicalinformation.astrazeneca-us.com/home/prescribing-information/fasenra-pi.html Date last accessed: January 2021.
  115. ↵
    1. AstraZeneca
    . Fasenra (Benralizumab) Summary of Product Characteristics. www.ema.europa.eu/en/documents/product-information/fasenra-epar-product-information_en.pdf Date last accessed: January 2021.
  116. ↵
    1. Bel EH,
    2. Wenzel SE,
    3. Thompson PJ, et al.
    Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371: 1189–1197. doi:10.1056/NEJMoa1403291
    OpenUrlCrossRefPubMed
  117. ↵
    1. Teva Pharmaceutical Industries
    . Press Release: Teva Announces Top-Line Results from Phase III Studies of Subcutaneously Administered Reslizumab in Patients with Severe Eosinophilic Asthma. 22 January 2018. www.businesswire.com/news/home/20180122005789/en/Teva-Announces-Top-Line-Results-Phase-III-Studies Date last accessed: January 2021.
  118. ↵
    1. Castro M,
    2. Zangrilli J,
    3. Wechsler ME, et al.
    Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015; 3: 355–366. doi:10.1016/S2213-2600(15)00042-9
    OpenUrl
  119. ↵
    1. Teva
    . A Phase 3, 24-Week Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Reslizumab Subcutaneous Dosing (110 mg Every 4 Weeks) in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils. NCT02501629. https://clinicaltrials.gov/ct2/show/NCT02501629?term=reslizumab&cntry=US&draw=2&rank=10. Date last accessed: January 2021. Date last updated: 9 November 2021.
  120. ↵
    1. FitzGerald JM,
    2. Bleecker ER,
    3. Nair P, et al.
    Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016; 388: 2128–2141. doi:10.1016/S0140-6736(16)31322-8
    OpenUrlCrossRefPubMed
  121. ↵
    1. Kavanagh J,
    2. Roxas C,
    3. Green L, et al.
    Super-responder analysis and real-world one year effectiveness of benralizumab in severe eosinophilic asthma. Eur Respir J 2020; 56: Suppl, 64, 2261. doi:10.1183/13993003.congress-2020.2261
    OpenUrlCrossRef
  122. ↵
    1. Castro M,
    2. Corren J,
    3. Pavord ID, et al.
    Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 2018; 378: 2486–2496. doi:10.1056/NEJMoa1804092
    OpenUrlCrossRefPubMed
    1. Tepper RS,
    2. Wise RS,
    3. Covar R, et al.
    Asthma outcomes: pulmonary physiology. J Allergy Clin Immunol 2012; 129: Suppl., S65–S87. doi:10.1016/j.jaci.2011.12.986
    OpenUrlCrossRefPubMed
    1. Castro M,
    2. Corren J,
    3. Pavord ID, et al.
    A randomized, controlled phase 3 study, LIBERTY ASTHMA QUEST, evaluating the efficacy and safety of dupilumab in uncontrolled moderate-to-severe asthma. Am J Respir Crit Care Med 2018; 197: A7700.
    OpenUrl
  123. ↵
    1. Juniper EF,
    2. Svensson K,
    3. Mörk AC, et al.
    Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005; 99: 553–558. doi:10.1016/j.rmed.2004.10.008
    OpenUrlCrossRefPubMed
  124. ↵
    1. Rabe KF,
    2. Nair P,
    3. Brusselle G, et al.
    Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 2018; 378: 2475–2485. doi:10.1056/NEJMoa1804093
    OpenUrlCrossRefPubMed
  125. ↵
    1. Pardini C
    . Nasal Polyps Do Not Impair Mepolizumab Efficacy in Eosinophilic Asthma. MPR First Report, AAAI 2017. 4 March 2017. www.empr.com/home/mpr-first-report/aaaai-2017/nasal-polyps-do-not-impair-mepolizumab-efficacy-in-eosinophilic-asthma/ Date last accessed: January 2021.
  126. ↵
    1. Liu M,
    2. Keene O,
    3. Yancey S, et al.
    Efficacy of mepolizumab in patients with severe eosinophilic asthma and nasal polyps. J Allergy Clin Immunol 2017; 139: AB8. doi:10.1016/j.jaci.2016.12.082
    OpenUrl
  127. ↵
    1. Maspero J,
    2. Harrison T,
    3. Werkström V, et al.
    Clinical efficacy of benralizumab in patients with severe, uncontrolled eosinophilic asthma and nasal polyposis: pooled analysis of the SIROCCO and CALIMA trials. J Allergy Clin Immunol 2018; 141: AB12. doi:10.1016/j.jaci.2017.12.038
    OpenUrl
  128. ↵
    1. Castro M,
    2. Mathur S,
    3. Hargreave F, et al.
    Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011; 184: 1125–1132. doi:10.1164/rccm.201103-0396OC
    OpenUrlCrossRefPubMed
  129. ↵
    1. Weinstein SF,
    2. Katial RK,
    3. Bardin P, et al.
    Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract 2019; 7: 589–596. doi:10.1016/j.jaip.2018.08.021
    OpenUrl
  130. ↵
    1. Han JK,
    2. Bachert C,
    3. Desrosiers M, et al.
    Efficacy and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps: results from the randomized phase 3 Sinus-24 study. J Allergy Clin Immunol 2019; 143: AB422. doi:10.1016/j.jaci.2018.12.948
    OpenUrl
  131. ↵
    1. Bachert C,
    2. Desrosiers M,
    3. Mullol J, et al.
    A randomized phase 3 study, Sinus-52, evaluating the efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 2019; 143: AB433. doi:10.1016/j.jaci.2018.12.980
    OpenUrl
  132. ↵
    1. Pavord ID,
    2. Ford L,
    3. Sher L, et al.
    Dupilumab efficacy in asthma patients with comorbid chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST. Eur Respir J 2018; 52: Suppl. 62, OA1651. doi:10.1183/13993003.congress-2018.OA1651
    OpenUrlCrossRef
    1. Corren J,
    2. Castro M,
    3. Maspero JF, et al.
    Dupilumab improves asthma-related patient reported outcomes in asthma patients with chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST. Eur Respir J 2018; 52: Suppl. 62, PA1124. doi:10.1183/13993003.congress-2018.PA1124
    OpenUrlCrossRef
  133. ↵
    1. Busse W,
    2. Maspero JF,
    3. Katelaris CH, et al.
    Dupilumab improves SNOT-22 scores in asthma patients with chronic rhinosinusitis or nasal polypsosis (CRS/NP) in LIBERTY ASTHMA QUEST. Eur Respir J 2018; 52: Suppl. 62, PA1125. doi:10.1183/13993003.congress-2018.PA1125
    OpenUrlCrossRef
  134. ↵
    1. Rabe K,
    2. Castro M,
    3. Nair P, et al
    . Dupilumab reduces oral corticosteroid (OCS) use and severe exacerbations, and improves FEV1 in OCS-dependent, severe asthma with comorbid chronic rhinosinusitis with and without nasal polyps. Allergy 2019; 74: Suppl. 106, OA0055.
    OpenUrl
  135. ↵
    1. Cho S,
    2. Maspero JF,
    3. Canonica GW, et al.
    Dupilumab improves upper and lower airway outcome measures in patients with severe chronic rhinosinusitis with nasal polyps and comorbid asthma: pooled results from the SINUS-24 and SINUS-52 phase 3 studies. Am J Respir Crit Care Med 2019; 199: A7356. doi:10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A7356
    OpenUrl
  136. ↵
    1. Assaf SM,
    2. Hanania NA
    . Biological treatments for severe asthma. Curr Opin Allergy Clin Immunol 2019; 19: 379–386. doi:10.1097/ACI.0000000000000549
    OpenUrl
  137. ↵
    1. AstraZeneca
    . TEZSPIRE (Tezepelumab-Ekko) Summary of Product Characteristics. 2021. www.accessdata.fda.gov/drugsatfda_docs/label/2021/761224s000lbl.pdf Date last accessed: 1 February 2021.
PreviousNext
Back to top
Vol 8 Issue 3 Table of Contents
ERJ Open Research: 8 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Type 2 inflammation in asthma and other airway diseases
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Type 2 inflammation in asthma and other airway diseases
Jorge Maspero, Yochai Adir, Mona Al-Ahmad, Carlos A. Celis-Preciado, Federico D. Colodenco, Pedro Giavina-Bianchi, Hani Lababidi, Olivier Ledanois, Bassam Mahoub, Diahn-Warng Perng, Juan C. Vazquez, Arzu Yorgancioglu
ERJ Open Research Jul 2022, 8 (3) 00576-2021; DOI: 10.1183/23120541.00576-2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Type 2 inflammation in asthma and other airway diseases
Jorge Maspero, Yochai Adir, Mona Al-Ahmad, Carlos A. Celis-Preciado, Federico D. Colodenco, Pedro Giavina-Bianchi, Hani Lababidi, Olivier Ledanois, Bassam Mahoub, Diahn-Warng Perng, Juan C. Vazquez, Arzu Yorgancioglu
ERJ Open Research Jul 2022, 8 (3) 00576-2021; DOI: 10.1183/23120541.00576-2021
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Epidemiology
    • Burden of disease
    • Type 2 inflammation: pathophysiology
    • Biomarkers for type 2 inflammation
    • Management of severe asthma and other airway diseases with type 2 inflammation
    • Conclusions
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Asthma and allergy
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Role of digital health in pulmonary rehabilitation
  • Healthcare experiences of adults with COPD in community care
  • Multimorbidity in bronchiectasis
Show more Reviews

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2023 by the European Respiratory Society